Event
Mechanisms of Action of Psychedelics – Implication for Psychedelic-Assisted Therapy
Research on the clinical application of psychedelics is gaining momentum. However major knowledge gaps remain regarding the mechanisms of action underlying beneficial therapeutic effects of these substances. Understanding the clinical mechanisms of action will help to inform, optimize, and advance currently implemented psychotherapeutic approaches in the context of psychedelic-assisted therapy. Testing these approaches empirically is essential to be able to provide evidence-based psychedelic-assisted therapy and maximize the clinical potential of psychedelic substances in the treatment of psychiatric disorders. In this talk, I will present current insights into the mechanisms of action of psychedelics. Furthermore, I will discuss the implications these insights have for the conduction of psychedelic-assisted therapy and suggest potential synergistic effects between pharmacological mechanisms and non-pharmacological treatment approaches
Speakers
Senior Researcher, Psychologist, and Neuroscientist
Dr. Katrin Preller
University of Zürich and Yale University
View Speaker Profile
Related Events
‘Finding Gold in the Shadow’ – The Challenges of Psychedelic Therapy from a Psychotherapeutic Perspective
Keynotes & Talks
The benefits of psychedelic therapy have been very well documented over the past number of years, with cutting edge scientific research showing the healing potential of substances like psilocybin.
This presentation by Inwardbound co-founder…
Old Medicines, New Misunderstandings
Keynotes & Talks
Over two short years, Australia has gone from having no clinical psychedelic trials to multiple trials and training programs, substantial scientific, medical, and public interest, and a large government funding round specifically for psychedelic r…
Phase 3 Trial with Psilocybin‐assisted Therapy for Depression ‐ European Consortium
Keynotes & Talks
Psilocybin‐assisted therapy shows clear potential for depression and other indications in recent clinical trials. While there are two FDA Breakthrough designation programmes with psilocybin for depression in the US ﴾Usona Institute and Compass…
Psychedelics and meditation: a neurophilosophical perspective
Keynotes & Talks
Psychedelic ingestion and meditative practice are both ancient methods for altering consciousness that became widely known in Western society in the second half of the 20th century. Do the similarities begin and end t…
Pharmacology and Acute Effects of Different Psychedelics
Keynotes & Talks
Current clinical trials with psychedelics mostly use psilocybin. However, there are other classic psychedelics such as LSD, DMT and mescaline that may be useful. The presentation will give an overview on the substances currently used in clinical t…
